GNGBY
Getinge AB (publ)
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Last price
25.74
▼ 0.06 (0.24%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
25.74
Prev close
25.80
Day high
25.84
Day low
25.80
Volume
102
Market cap
$7.01B
P/E (TTM)
24.75
52W range
18.99 – 25.93
Day trading desk
Gap from prior close
-0.24%
Prior close 25.80
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
25.74 – 25.74
Position in range
—
—
ATR (14D)
0.17
0.67% of price
Prior day high
25.93
PDH
Prior day low
25.80
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 2.05K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+2.32%
+3.7%
1M
+9.92%
+6.2%
3M
+21.46%
+18.4%
6M
+14.77%
+3.7%
YTD
+8.83%
-3.5%
1Y
+19.27%
-0.7%
3Y
+53.29%
-20.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on GNGBY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$7.01B
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA$5.89B
Net income—
EPS (TTM)$1.04
Free cash flow$2.85B
Total cash—
Total debt—
Book value / share$107.12
Shares outstanding254.15M
Float178.53M
Short % of float—
Dividend yield1.99%
Beta (5Y)0.83
Valuation & profitability ratios
Trailing P/E24.75
Forward P/E—
PEG ratio1.70
Price / sales—
Price / book0.24
EV / revenue—
EV / EBITDA—
Gross margin48.60%
Operating margin0.00%
Profit margin7.82%
Return on equity8.95%
Return on assets5.25%
Debt / equity35.81
Current ratio1.31
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $34.97B | $34.76B | $31.83B | $28.29B | +0.6% |
| Operating revenue | $34.97B | $34.76B | $31.83B | $28.29B | +0.6% |
| Cost of revenue | $18.32B | $18.61B | $17.33B | $14.88B | -1.6% |
| Gross profit | $16.65B | $16.15B | $14.49B | $13.41B | +3.1% |
| Research & development | $1.45B | $1.43B | $1.19B | $1.19B | +1.5% |
| Selling, general & admin | $9.53B | $9.59B | $8.70B | $8.39B | -0.7% |
| Total operating expense | $12.19B | $12.46B | $10.80B | $9.53B | -2.1% |
| Operating income | $4.46B | $3.70B | $3.69B | $3.88B | +20.8% |
| Net interest income | -$613.00M | -$562.00M | -$370.00M | -$174.00M | -9.1% |
| Pre-tax income | $3.15B | $2.28B | $3.34B | $3.47B | +37.8% |
| Tax provision | $869.00M | $628.00M | $915.00M | $956.00M | +38.4% |
| Net income | $2.26B | $1.64B | $2.41B | $2.49B | +37.9% |
| Net income to common | $2.26B | $1.64B | $2.41B | $2.49B | +37.9% |
| Basic EPS | 8.29 | 6.01 | 8.86 | 9.15 | +37.9% |
| Diluted EPS | 8.29 | 6.01 | 8.86 | 9.15 | +37.9% |
| EBIT | $3.81B | $2.89B | $3.81B | $3.68B | +31.8% |
| EBITDA | $6.05B | $5.31B | $5.91B | $5.70B | +14.0% |
| Basic shares | 272.37M | 272.37M | 272.37M | 272.37M | 0.0% |
| Diluted shares | 272.37M | 272.37M | 272.37M | 272.37M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $3.40B | $2.96B | $2.73B | $5.68B | +14.9% |
| Cash & short-term investments | $3.40B | $2.96B | $2.73B | $5.68B | +14.9% |
| Accounts receivable | $5.78B | $6.35B | $5.74B | $5.28B | -8.9% |
| Inventory | $6.02B | $6.59B | $6.42B | $6.23B | -8.7% |
| Total current assets | $17.23B | $18.16B | $16.65B | $19.11B | -5.1% |
| Property, plant & equipment | $4.94B | $5.70B | $5.21B | $4.87B | -13.3% |
| Goodwill & intangibles | $33.51B | $39.24B | $30.67B | $27.01B | -14.6% |
| Total assets | $56.51B | $63.92B | $53.59B | $52.03B | -11.6% |
| Total current liabilities | $13.04B | $15.05B | $13.19B | $11.99B | -13.3% |
| Current debt | $1.51B | $1.96B | $2.69B | $410.00M | -22.8% |
| Long-term debt | $7.89B | $6.97B | $3.90B | $4.10B | +13.2% |
| Total debt | $10.88B | $10.73B | $8.08B | $5.82B | +1.5% |
| Total liabilities | $27.01B | $30.71B | $23.18B | $21.58B | -12.0% |
| Retained earnings | $21.50B | $20.33B | $19.86B | $18.80B | +5.8% |
| Shareholder equity | $29.43B | $33.01B | $30.17B | $30.04B | -10.8% |
| Working capital | $4.18B | $3.12B | $3.46B | $7.11B | +34.3% |
| Net tangible assets | -$4.08B | -$6.24B | -$504.00M | $3.03B | +34.5% |
| Shares issued | 272.37M | 272.37M | 272.37M | 272.37M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $3.79B | $2.85B | $3.74B | $3.63B | +32.8% |
| Depreciation & amortisation | $2.25B | $2.42B | $2.09B | $2.03B | -7.1% |
| Change in working capital | -$1.19B | -$458.00M | -$1.64B | -$1.24B | -159.2% |
| Operating cash flow | $3.95B | $4.58B | $2.96B | $3.37B | -13.7% |
| Capital expenditure | -$1.31B | -$1.31B | -$1.35B | -$1.14B | -0.4% |
| Investing cash flow | -$2.96B | -$4.55B | -$6.54B | -$1.47B | +34.9% |
| Dividends paid | -$1.27B | -$1.23B | -$1.18B | -$1.11B | -3.3% |
| Financing cash flow | -$765.00M | $504.00M | $511.00M | -$500.00M | -251.8% |
| Free cash flow | $2.63B | $3.27B | $1.60B | $2.23B | -19.4% |
| End cash position | $3.40B | $2.96B | $2.73B | $5.68B | +14.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $8.38B | $7.44B | $10.19B | $8.24B | $8.32B | +12.6% |
| Operating revenue | $8.38B | $7.44B | $10.19B | $8.24B | $8.32B | +12.6% |
| Cost of revenue | $3.96B | $3.84B | $5.38B | $4.30B | $4.22B | +3.3% |
| Gross profit | $4.42B | $3.61B | $4.80B | $3.94B | $4.09B | +22.5% |
| Research & development | $358.00M | $328.00M | $485.00M | $343.00M | $318.00M | +9.1% |
| Selling, general & admin | $2.45B | $2.31B | $2.45B | $2.35B | $2.48B | +6.0% |
| Total operating expense | $3.06B | $2.87B | $3.39B | $3.05B | $3.20B | +6.9% |
| Operating income | $1.35B | $738.00M | $1.41B | $895.00M | $896.00M | +83.1% |
| Net interest income | -$133.00M | -$135.00M | -$164.00M | -$147.00M | -$170.00M | +1.5% |
| Pre-tax income | $1.15B | $573.00M | $1.21B | $721.00M | $428.00M | +100.9% |
| Tax provision | $312.00M | $170.00M | $338.00M | $194.00M | $124.00M | +83.5% |
| Net income | $841.00M | $401.00M | $868.00M | $524.00M | $300.00M | +109.7% |
| Net income to common | $841.00M | $401.00M | $868.00M | $524.00M | $300.00M | +109.7% |
| Basic EPS | 3.09 | 1.47 | 3.19 | 1.92 | 1.10 | +110.2% |
| Diluted EPS | 3.09 | 1.47 | 3.19 | 1.92 | 1.10 | +110.2% |
| EBIT | $1.35B | $738.00M | $1.41B | $895.00M | $896.00M | +83.1% |
| EBITDA | $1.85B | $1.22B | $2.06B | $1.41B | $1.46B | +51.8% |
| Basic shares | 272.37M | 272.37M | 272.37M | 272.37M | 272.37M | 0.0% |
| Diluted shares | 272.37M | 272.37M | 272.37M | 272.37M | 272.37M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.05B | $4.02B | $3.40B | $1.95B | $4.20B | -49.0% |
| Cash & short-term investments | $2.05B | $4.02B | $3.40B | $1.95B | $4.20B | -49.0% |
| Accounts receivable | $5.09B | $4.93B | $5.78B | $4.79B | $5.26B | +3.2% |
| Inventory | $6.84B | $6.58B | $6.02B | $6.79B | $6.65B | +4.0% |
| Total current assets | $15.77B | $17.44B | $17.23B | $15.73B | $18.16B | -9.6% |
| Property, plant & equipment | $5.14B | $5.02B | $4.94B | $5.06B | $5.19B | +2.4% |
| Goodwill & intangibles | $35.56B | $34.66B | $33.51B | $34.69B | $35.99B | +2.6% |
| Total assets | $57.37B | $58.02B | $56.51B | $56.37B | $60.27B | -1.1% |
| Total current liabilities | $12.03B | $12.93B | $13.04B | $12.85B | $13.89B | -6.9% |
| Current debt | $1.53B | $1.53B | $1.51B | $1.75B | $1.77B | +0.5% |
| Long-term debt | $7.94B | $7.95B | $7.89B | $7.91B | $8.12B | -0.1% |
| Total debt | $11.10B | $10.99B | $10.88B | $11.17B | $11.48B | +1.0% |
| Total liabilities | $26.37B | $26.98B | $27.01B | $27.35B | $29.52B | -2.2% |
| Retained earnings | $21.48B | $21.96B | $21.50B | $19.95B | $20.70B | -2.2% |
| Shareholder equity | $30.95B | $30.98B | $29.43B | $28.82B | $30.55B | -0.1% |
| Working capital | $3.73B | $4.51B | $4.18B | $2.88B | $4.28B | -17.2% |
| Net tangible assets | -$4.61B | -$3.68B | -$4.08B | -$5.87B | -$5.44B | -25.3% |
| Shares issued | 272.37M | 272.37M | 272.37M | 272.37M | 272.37M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $1.28B | $707.00M | $1.37B | $867.00M | $598.00M | — | +81.6% |
| Depreciation & amortisation | $504.00M | $484.00M | $654.00M | $514.00M | $566.00M | — | +4.1% |
| Change in working capital | -$174.00M | $242.00M | -$256.00M | -$214.00M | -$662.00M | — | -171.9% |
| Operating cash flow | $1.29B | $1.11B | $1.55B | $841.00M | $470.00M | — | +16.7% |
| Capital expenditure | -$296.00M | -$268.00M | -$370.00M | -$335.00M | -$313.00M | — | -10.4% |
| Investing cash flow | -$1.73B | -$264.00M | -$447.00M | -$1.82B | -$401.00M | — | -554.2% |
| Dividends paid | -$1.30B | — | -$4.00M | -$1.26B | — | -$12.00M | — |
| Financing cash flow | -$1.49B | -$189.00M | -$625.00M | -$1.47B | $1.14B | — | -688.9% |
| Free cash flow | $995.00M | $838.00M | $1.18B | $506.00M | $157.00M | — | +18.7% |
| End cash position | $2.05B | $4.02B | $3.40B | $1.95B | $4.20B | — | -49.0% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $8.37B | +1.8% |
| Next quarter | — | — | $10.79B | +5.9% |
| Current year | — | — | $35.16B | +0.6% |
| Next year | — | — | $37.08B | +5.5% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.00%
Held by institutions0.00%
Institutions holding2
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
25.30
+1.74% from price
SMA 20
25.02
+2.87% from price
SMA 50
22.82
+12.81% from price
SMA 100
21.67
+18.76% from price
SMA 200
21.96
+17.18% from price
EMA 12
25.26
+1.91% from price
EMA 26
24.49
+5.08% from price
EMA 50
23.44
+9.82% from price
RSI (14)
75.8
Overbought
MACD (12,26,9)
0.76
Hist -0.06
ATR (14)
0.17
0.67% of price
Realised vol 30D
33.7%
Annualised
Bollinger upper
25.99
20, 2σ
Bollinger lower
24.05
20, 2σ
50 / 200 cross
Golden
22.82 vs 21.96
Trend bias
Above 200
+17.18%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.76
Less volatile than market
Correlation to SPY
0.33
Loosely linked
Realised vol 30D
33.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-22.9%
Peak to trough
Max drawdown 5Y
-69.4%
Peak to trough
ATR 14
0.17
0.67% of price
Beta (reported)
0.83
5Y monthly, from filing
Dividends & splits
Forward rate$0.51 / yr
Forward yield1.99%
5-year avg yield1.89%
Payout ratio48.48%
Ex-dividend dateApr 23, 2026
Next pay dateMay 13, 2026
Last split—
Split date—
Headlines
MTD Second Quarter Earnings Beat Estimates on China-Led Sales Growth
Zacks · 20d ago
Getinge Interim Report April-June 2026: Good organic growth, high profitability and strong cash flow
PR Newswire · 38d ago
Global Medical Ventilators Market Report 2025-2030 Just Released; Comprehensive Profiles of Getinge, Drägerwerk, Philips, Medtronic, and ResMed
GlobeNewswire · 45d ago
Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member
Business Wire · 53d ago
[Latest] Global Neonatal Intensive Care Respiratory Devices Market Size/Share Worth USD 5.7 Billion by 2035 at a 10.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, SWOT Analysis)
GlobeNewswire · 60d ago
Getinge Launches Vasoview Hemopro 3, Advancing Endoscopic Vessel Harvesting
PR Newswire · 82d ago
Is Avantor (AVTR) Elevating Quality To A Strategic Edge With Its New Regulatory Chief?
Simply Wall St. · 83d ago
Getinge's subsidiary Maquet Cardiovascular receives adverse jury trial verdict in patent infringement dispute with Abiomed in the U.S.
PR Newswire · 87d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.